Charles River Laboratories saw only slight growth in revenue compared to the same quarter last year, which was driven by its safety assessment and endotoxin and microbial detection businesses, and double-digit revenue increases from mid-tier biotech clients.
Lab Corp will buy Covance for $6.1bn in a surprise deal that follows another quarter in which early phase gains were offset by underperformance in central labs.
Despite a strong Q3, Icon has outlined plans for further cuts at its UK clinical pharmacology unit (CPU) as it rejigs its ‘weak’ early phase services business.
Production by Ireland’s pharmaceutical sector fell sharply in September but it is too early to say if it was part of a longer term decline, says the CSO
Ashland will buy International Specialty Products (ISP) in a deal designed to expand it's business in less cyclical, high-growth markets such as pharmaceuticals and personal care.
Australia’s CSL Ltd has signed a $3.1bn agreement to acquire Talecris Biotherapeutics of the US and throw down the gauntlet to rival Baxter International in the plasma-based pharmaceutical sector.
The lacklustre performance of Millipore’s bioprocess division has continued into the second quarter of the year with revenues reaching $229.8m (€147m) up just one per cent on the comparable 2007 quarter.
Niro Pharma Systems unit Courtoy has improved its MODUL rotary
tablet press range with the launch of the MODUL D, a double-sided
version that ramps up the unit's production capabilities, writes
Phil Taylor.
German biotech company Evotec OAI boosted its second quarter
revenues by 18 per cent to €17 million, despite the difficult
operating environment for companies supplying drug discovery
technologies, continuing its recovery from a weak...
The Netherlands-based pharmaceuticals, coatings and chemicals firm
Akzo Nobel has posted a 7 per cent rise in net income to €176
million for the first quarter of 2004, a little more than expected,
but has warned that its pharmaceuticals...
